Login / Signup

Open-Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy.

Lawren VandeVredeMarian L DaleScott FieldsMegan FrankEmma HareHilary W HeuerKellie KeithMary KoestlerPeter A LjubenkovDana McDermottNoelle OhanesianJennifer RichardsJulio C RojasElisabeth H ThijssenChristine WalshPing WangAmy WolfJoseph F QuinnRichard TsaiAdam L Boxer
Published in: Movement disorders clinical practice (2020)
Neither salsalate nor young plasma had a detectable effect on disease progression in PSP-RS. Focused open-label clinical trials incorporating historical clinical, neuropsychological, fluid, and imaging biomarkers provide useful preliminary data about the promise of novel PSP-directed therapies.
Keyphrases